Contrave Tablet, Extended Release
Product Images NDC 51267-890

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Contrave (NDC 51267-890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nalpropion Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Contrave Er 01)

A data table presenting weight (in pounds and kilograms) and height (in inches and centimeters), with cells containing numeric values. The table is color-coded with some cells highlighted in green, indicating specific data points across the weight and height ranges.*

FDA Label Image

Naltrexone Hydrochloride Chemical Structure (Contrave Er 02)

Chemical structure of naltrexone hydrochloride, an active ingredient in Contrave Extended-Release tablets. The diagram shows the molecular arrangement including rings and functional groups characteristic of naltrexone with the hydrochloride salt.*

FDA Label Image

Bupropion Hydrochloride Chemical Structure (Contrave Er 03)

Chemical structure of naltrexone hydrochloride, one of the active ingredients in Contrave Extended-Release tablets. The diagram shows the molecular framework including a chlorine atom and hydrochloride group.*

FDA Label Image

Figure 1 (Contrave Er 04)

A line graph depicting weight change from baseline (%) over 56 weeks comparing placebo and Contrave Extended-Release (32/360 mg). The x-axis represents weeks, and the y-axis represents percent weight change. The graph shows that subjects on Contrave experienced a greater weight loss than those on placebo throughout the study period.*

FDA Label Image

Figure 1 (Contrave Er 05)

A line graph comparing weight change from baseline (%) over 56 weeks between Placebo and Contrave Extended-Release (32/360 mg). The x-axis represents weeks, and the y-axis shows percentage weight change. The graph shows weight steadily decreasing more with Contrave than with placebo over time, with data for completers followed by ITT-LOCF analysis.*

FDA Label Image

Figure 1 (Contrave Er 06)

A line chart depicting percent weight change from baseline over 56 weeks for two groups: Placebo (open circles) and Contrave 32/360 (filled triangles). The x-axis shows weeks, and the y-axis shows weight change percentage. The chart includes data for completers and ITT-LOCF analyses, with Contrave showing greater weight loss than placebo throughout the study period.*

FDA Label Image

8 mg/90 mg 120-count Bottle Label (Contrave Er 07)

Label for Contrave Extended-Release Tablets containing 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride per tablet. The oral extended-release tablets come in a package of 120. Distributed by Currax Pharmaceuticals LLC, the label includes storage instructions and a notice not to cut, chew, or crush the tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.